Gilead (Nasdaq: GILD) and AbbVie (NYSE: ABBV) Hep. C drugs were both given prefered status at Prime. A press release is below.
People
with Hepatitis C who are served by pharmacy benefit manager Prime
Therapeutics LLC (Prime) will now have greater support for the treatment
recommended by their physician. This is a result of new agreements
between Prime and pharmaceutical companies Gilead Sciences and AbbVie.
Beginning immediately, the agreements place both Gilead's Harvoni® and
AbbVie's Viekira Pak® on Prime's preferred drug list (formulary),
meaning members can more easily get the medicine they need to feel
better and live well.
"There has been a substantial reduction in
the net price of both of these drugs just in the past few weeks, so
sometimes it pays not to go first," said Peter Wickersham, senior vice
president of Integrated Care and Specialty, Prime. "It was clear that
neither Gilead nor AbbVie wanted to be left off our formulary and the
result proved to be significantly better than taking an exclusive
position."
Read more... Labels: Abbvie, Gilead, insurance coverage, Prime